Videos

Featured Video

Beyond the NCCN Localized Prostate Cancer Risk Category: The MMAI Prognostic Risk Stratification Model – Jonathan Tward
March 13, 2023

Jonathan Tward joins Alicia Morgans to discuss advancing prognostic capabilities in prostate cancer risk stratification using multimodal deep learning with digital histopathology within the context of a series of NRG Oncology phase III trials. The Artera AI prognostic biomarker model is based on five prospectively randomized trials of over 5,500 patients with low-risk prostate cancer on radiation...

March 10, 2023
Multi-Modal Artificial Intelligence (MMAI) Prognostic Biomarker in High-Risk Prostate Cancer – Daniel Spratt

Alicia Morgans and Daniel Spratt discuss an AI-derived multi-modal digital pathology-based biomarker test designed towards improving risk stratification in high risk prostate cancer and then supporting personalized treatment decisions...

February 8, 2023
Artificial Intelligence Transformative in Prostate Cancer Patient Care – Felix Feng

Felix Feng joins Alicia Morgans to discuss how the application of artificial intelligence (AI) is transformative in prostate cancer care. Dr. Feng focuses on how AI will assist physicians...

January 22, 2023
Who is ARTERA? – Andre Esteva

Andre Esteva, CEO of Artera Inc joins Alicia Morgans in a discussion about Artera, which has developed an artificial intelligence-derived digital pathology-based biomarker test for prostate cancer that enables...

January 22, 2023
Beyond Genomics: AI Informing Decision Making in Prostate Cancer – Ashley Ross

In this conversation, Alicia Morgans and Ashley Ross discuss the current clinical landscape of how risk is defined in localized prostate cancer...